So far at least two enzymes have been found to catalyse the activation of zylnogen plasminogen to plasmin; these are urokinase type plasminogen activator (uPA) and tissue type plasminogen activator [l]. Generation of the broad-spectrum protease, plasmin, by uPA is involved in degradation of extracellular matrix (ECM) proteins in a variety of normal and pathological processes [2] . Plasmin formation takes place at the cell surface and is regulated in a complex way involving plasminogen activator inhibitors, proenzyme activation, the substrate and via specific receptors for plasminogen and plasminogen activator [3] . The specific receptor (uPAR) for uPA is at the core of this regulation. In fibroblastlike cells the receptor is localised to regions of cell contact and would therefore influence which regions of the ECM immediately surrounding the cell are degraded. The human uPAR is a relatively small protein of 313 amino acid residues [4] and is associated with the cell membrane via a glycosyl phosphatidyl inositol (GPI) anchor [5] . uPAR was first detected on monocytes and monocyte-like cells by a specific, high affinity binding of uPA and its zymogen pro-uPA [6] . The receptor has since been found in a large number of cultured cell lines of neoplastic and non-neoplast ic origins. In mouse gastrointestinal epithelial cells, two versions of the receptor have been described [7] (shown in fig 1) . The major differences between these receptors is the lack of a site for GPI addition in the smaller version of the receptor and consequently it is thought to be secreted from the cell [ 7 ] .
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(11) 239 Here we describe a sequence of a urokinase receptor, isolated in addition to that previously isolated from the human monocytelike, macrophage cell line U937 (fig 1 sequence V) . This novel receptor is missing 45 amino acid residues 136-181 which proceeds a highly conserved region found in all urokinase receptors involved in ligand binding. As the ligand binding domain is completely contained within residues 1-87 [8] , it is expected that ligand binding of this form of the receptor will remain unaltered. The loss of amino acids 136-181 removes two potential N-glycosylation sites, (residues 162,172), 5 cysteine residues and 28 polar or charged amino acids. These differences in sequence between the receptor previously isolated from U937 cells (fig 1. 11 ) and the novel form of receptor described here may have consequences in affecting the level of glycosylation and the folding of the receptor. These features may render this receptor more susceptible to proteolysis than versions of the receptor containing this region. In addition, the highly polar nature of the missing sequence may influence the nature of interactions with other molecules at the cell surface of monocytes.
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